Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.71 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.58 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.58 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | B4GALT1 | P15291 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CD69 | Q07108 | 1/20 | 0.45 |
| ▸ | MDK | P21741 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18784372 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL19502532 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL22152872 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL24080958 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL14971310 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL25098132 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL22171056 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL24046086 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL20942623 | 1.00 | MAPK1 (0.71) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 | |
| SCHEMBL26877321 | 0.96 | MAPK1 (0.69) | MAPK1LGALS3LGALS8LGALS4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 359 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240240182-A1 | HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-18 | — | — | US | disclosed |
| US-20240218366-A1 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-07-04 | — | — | US | disclosed |
| US-20240209372-A1 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-06-27 | — | — | US | disclosed |
| US-20240209369-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2024-06-27 | — | — | US | disclosed |
| US-20240209373-A1 | ELONGATION OF VERY LONG CHAIN FATTY ACIDS PROTEIN 1 (ELOVL1) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | US | disclosed |
| WO-2024077148-A1 | PLASMINOGEN (PLG) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-11 | — | — | WO | disclosed |
| WO-2024073709-A2 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-04-04 | — | — | WO | disclosed |
| WO-2024059165-A1 | 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| US-11873491-B2 | Complement component C5 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| WO-2024006953-A2 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| WO-2017048843-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-3141265-A1 | CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDES | Alnylam Pharmaceuticals, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-20170067060-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF CD274/PD-L1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-03-09 | — | — | US | disclosed |
| WO-2017035340-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | WO | disclosed |
| US-9574192-B2 | Serapina1 iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-21 | — | — | US | disclosed |
| WO-2017023660-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-02-09 | — | — | WO | disclosed |
| US-20170029817-A1 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES | ALNYLAM PHARMACEUTICALS, INC. | 2017-02-02 | — | — | US | disclosed |
| US-20170029815-A1 | RNAi AGENTS MODIFIED AT THE 4'-C POSITION | BANK OF AMERICA, N.A. | 2017-02-02 | — | — | US | disclosed |
| WO-2017015109-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-01-26 | — | — | WO | disclosed |
| WO-2017011286-A1 | INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN, ACID LABILE SUBUNIT (IGFALS) AND INSULIN-LIKE GROWTH FACTOR 1 (IGF-1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2017-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218366-A1 | COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | F5, F13B, F12 | MAPK1 4833/4885LGALS3 3921/4885LGALS8 2909/4885 |
| US-11873491-B2 | Complement component C5 iRNA compositions and methods of use thereof | C5, RNASEH1, RNASEL | MAPK1 4781/4885LGALS3 2960/4885LGALS8 2589/4885 |
| US-20240209372-A1 | PROLINE DEHYDROGENASE 2 (PRODH2) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | RNASEH1, IMPDH2, RNASEL | MAPK1 4640/4885LGALS3 4298/4885LGALS8 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.